Aktis Oncology, Inc. SEC filings AKTS

Aktis Oncology, Inc. has 62 filings in SEC EDGAR's recent list, going back to Oct 2, 2024. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 13, 2026 (results of operations). The company's fiscal year ends on December 31.

Aktis Oncology, Inc. SEC filings
Form Description Filed Period
10-Q Quarterly report Aug 13, 2026 Jun 30, 2026
8-K Current report
Results of operations
Aug 13, 2026 Aug 13, 2026
10-Q Quarterly report May 11, 2026 Mar 31, 2026
8-K Current report
Results of operations
May 11, 2026 May 11, 2026
8-K Current report
Officer or director change, Regulation FD disclosure
Apr 16, 2026 Apr 15, 2026
8-K Current report
Results of operations
Mar 30, 2026 Mar 30, 2026
10-K Annual report Mar 30, 2026 Dec 31, 2025
S-8 Employee stock plan registration Jan 12, 2026 —
8-K Current report
Bylaw or fiscal year change
Jan 12, 2026 Jan 12, 2026
424B4 Prospectus Jan 9, 2026 —
EFFECT Filing Jan 8, 2026 —
CERT Filing Jan 8, 2026 —
8-A12B Filing Jan 7, 2026 —
S-1/A Amended registration statement Jan 7, 2026 —
S-1/A Amended registration statement Jan 5, 2026 —
S-1 Registration statement Dec 19, 2025 —
DRS/A Filing Nov 14, 2025 —
DRS/A Filing May 22, 2025 —
DRS/A Filing Dec 13, 2024 —
DRS/A Filing Nov 22, 2024 —
DRS Filing Oct 11, 2024 —
D Filing Oct 2, 2024 —

Showing 22 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
AKTS (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Boston, MA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
2035832

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.